TY  - JOUR
AU  - Pereira, Fernando
AU  - Serrano, Angel
AU  - Manzanedo, Israel
AU  - Perez-Viejo, Estibalitz
AU  - Gonzalez-Moreno, Santiago
AU  - Gonzalez-Bayon, Luis
AU  - Arjona-Sanchez, Alvaro
AU  - Torres, Juan
AU  - Ramos, Isabel
AU  - Barrios, Maria E
AU  - Cascales, Pedro
AU  - Morales, Rafael
AU  - Boldo, Enrique
AU  - Garcia-Fadrique, Alfonso
AU  - Arteaga, Xabier
AU  - Gutierrez-Calvo, Alberto
AU  - Sanchez-Garcia, Susana
AU  - Asensio, Enrique
AU  - Ramirez, Cesar P
AU  - Artiles, Manuel
AU  - Vaque, Javier
AU  - Parra, Pedro A
AU  - Villarejo, Pedro
AU  - Muñoz-Casares, Cristobal
AU  - Turienzo, Estrella
AU  - Calero, Alicia
AU  - Jaen-Torrejimeno, Isabel 
AU  - Prieto, Isabel
AU  - Galindo, Julio
AU  - Borrego, Vicente
AU  - Marcello, Manuel E
AU  - Rihuete, Cristina
AU  - Carrasco, Joaquin
AU  - Gomez-Quiles, Luis
PY  - 2022
DO  - 10.1186/s12885-022-09572-7
UR  - http://hdl.handle.net/10668/20279
T2  - BMC cancer
AB  - The French PRODIGE 7 trial, published on January 2021, has raised doubts about the specific survival benefit provided by HIPEC with oxaliplatin 460 mg/m2 (30 minutes) for the treatment of peritoneal metastases from colorectal cancer. However, several...
LA  - en
PB  - BioMed Central
KW  - Colon cancer
KW  - HIPEC
KW  - Peritoneal carcinomatosis
KW  - Peritoneal metastases
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Colonic Neoplasms
KW  - Colorectal Neoplasms
KW  - Combined Modality Therapy
KW  - Cytoreduction Surgical Procedures
KW  - Humans
KW  - Hyperthermia, Induced
KW  - Hyperthermic Intraperitoneal Chemotherapy
KW  - Mitomycin
KW  - Percutaneous Coronary Intervention
KW  - Peritoneal Neoplasms
KW  - Prospective Studies
KW  - Rectal Neoplasms
KW  - Survival Rate
TI  - GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases.
TY  - research article
VL  - 22
ER  -